Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
6
USD
|
+2.39%
|
|
+1.69%
|
-7.55%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
178.6
|
504.1
|
401
|
388.1
|
-
|
-
|
Enterprise Value (EV)
1 |
130.9
|
360.8
|
321.1
|
168.2
|
188.8
|
119.7
|
P/E ratio
|
-3.2
x
|
-6.1
x
|
-5.11
x
|
-4.38
x
|
-4.33
x
|
-5.12
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
179
x
|
-
|
-
|
-
|
153
x
|
330
x
|
EV / Revenue
|
131
x
|
-
|
-
|
-
|
74.5
x
|
102
x
|
EV / EBITDA
|
-2.65
x
|
-5.86
x
|
-3.14
x
|
-1.53
x
|
-1.51
x
|
-0.83
x
|
EV / FCF
|
-3.11
x
|
-7.31
x
|
-4.76
x
|
-1.83
x
|
-1.87
x
|
-1
x
|
FCF Yield
|
-32.2%
|
-13.7%
|
-21%
|
-54.8%
|
-53.5%
|
-100%
|
Price to Book
|
1.11
x
|
1.32
x
|
1.81
x
|
1.53
x
|
2.21
x
|
2.14
x
|
Nbr of stocks (in thousands)
|
25,267
|
49,516
|
61,795
|
64,677
|
-
|
-
|
Reference price
2 |
7.070
|
10.18
|
6.490
|
6.000
|
6.000
|
6.000
|
Announcement Date
|
3/3/22
|
3/27/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
1
|
-
|
-
|
-
|
2.533
|
1.175
|
EBITDA
1 |
-
|
-36.63
|
-49.35
|
-61.54
|
-102.3
|
-109.7
|
-124.9
|
-143.4
|
EBIT
1 |
-70.2
|
-37.02
|
-49.86
|
-62.03
|
-102.6
|
-110.3
|
-126.1
|
-139.4
|
Operating Margin
|
-
|
-
|
-4,986%
|
-
|
-
|
-
|
-4,977.77%
|
-11,863.47%
|
Earnings before Tax (EBT)
1 |
-
|
-39.76
|
-49.65
|
-59.99
|
-89.97
|
-100.6
|
-121.8
|
-142.4
|
Net income
1 |
-
|
-29.35
|
-50.16
|
-60.34
|
-90.21
|
-100.5
|
-121.7
|
-142.5
|
Net margin
|
-
|
-
|
-5,015.8%
|
-
|
-
|
-
|
-4,804.89%
|
-12,130.43%
|
EPS
2 |
-26.74
|
-102.9
|
-2.210
|
-1.670
|
-1.270
|
-1.370
|
-1.385
|
-1.171
|
Free Cash Flow
1 |
-
|
-30.39
|
-42.17
|
-49.38
|
-67.44
|
-92.16
|
-100.9
|
-119.6
|
FCF margin
|
-
|
-
|
-4,216.7%
|
-
|
-
|
-
|
-3,983.86%
|
-10,182.27%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/20
|
3/30/21
|
3/3/22
|
3/27/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
2.34
|
-
|
-
|
EBITDA
1 |
-13.76
|
-13.68
|
-13.95
|
-17.18
|
-16.74
|
-24.08
|
-21.09
|
-33.11
|
-23.99
|
-
|
-27
|
-29
|
-30
|
-
|
-
|
EBIT
1 |
-13.88
|
-13.82
|
-14.08
|
-17.29
|
-16.83
|
-24.16
|
-21.16
|
-33.18
|
-24.06
|
-25.45
|
-27.25
|
-32.2
|
-30.11
|
-27.48
|
-25.54
|
Operating Margin
|
-1,387.8%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,286.79%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-13.81
|
-13.75
|
-13.92
|
-16.81
|
-15.5
|
-21.47
|
-17.82
|
-29.71
|
-20.97
|
-22.28
|
-24.5
|
-26
|
-27.5
|
-
|
-
|
Net income
1 |
-14.25
|
-13.77
|
-13.93
|
-16.82
|
-15.82
|
-21.47
|
-17.9
|
-29.77
|
-21.02
|
-22.37
|
-24.51
|
-26.01
|
-27.51
|
-
|
-
|
Net margin
|
-1,424.8%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,175.53%
|
-
|
-
|
EPS
2 |
-0.5600
|
-0.5500
|
-0.5500
|
-0.4400
|
-0.2900
|
-0.3100
|
-0.2500
|
-0.4200
|
-0.2900
|
-0.3000
|
-0.3298
|
-0.3321
|
-0.3310
|
-0.2992
|
-0.2878
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/3/22
|
5/16/22
|
8/8/22
|
11/9/22
|
3/27/23
|
5/15/23
|
8/8/23
|
11/14/23
|
3/14/24
|
5/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
62
|
47.7
|
143
|
79.9
|
220
|
199
|
268
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-30.4
|
-42.2
|
-49.4
|
-67.4
|
-92.2
|
-101
|
-120
|
ROE (net income / shareholders' equity)
|
-
|
-234%
|
-27.6%
|
-33.9%
|
-35%
|
-38.9%
|
-42.6%
|
ROA (Net income/ Total Assets)
|
-50.5%
|
-38.5%
|
-26.5%
|
-32.5%
|
-33.4%
|
-42.6%
|
-62.6%
|
Assets
1 |
58.1
|
130.2
|
227.5
|
277.8
|
301.2
|
285.9
|
227.6
|
Book Value Per Share
2 |
-412.0
|
6.340
|
7.690
|
3.580
|
3.910
|
2.710
|
2.810
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.58
|
0.34
|
0.28
|
0.05
|
0.92
|
0.7
|
0.73
|
Capex / Sales
|
-
|
34%
|
-
|
-
|
-
|
27.57%
|
62.1%
|
Announcement Date
|
3/30/21
|
3/3/22
|
3/27/23
|
3/14/24
|
-
|
-
|
-
|
Average target price
14.21
USD Spread / Average Target +136.90% Consensus |
1st Jan change
|
Capi.
|
---|
| -7.55% | 388M | | +67.53% | 63.85B | | -0.77% | 41.83B | | +45.66% | 40.65B | | -10.72% | 27.12B | | +13.30% | 26.52B | | -22.79% | 18.69B | | +4.70% | 12.73B | | +24.10% | 12.11B | | +27.41% | 12.07B |
Other Biotechnology & Medical Research
|